Research programme: rituximab biosimilar - Coherus BioSciences/Daiichi Sankyo

Drug Profile

Research programme: rituximab biosimilar - Coherus BioSciences/Daiichi Sankyo

Latest Information Update: 25 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Coherus Biosciences
  • Developer Coherus BioSciences; Daiichi Sankyo Company
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Chronic lymphocytic leukaemia; Follicular lymphoma; Microscopic polyangiitis; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Wegener's granulomatosis

Most Recent Events

  • 31 Dec 2017 Coherus BioSciences enters into a distribution agreement with Orox Pharmaceuticals for etanercept biosimilar in Caribbean (West Indies) and Latin America
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in USA (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Follicular lymphoma in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top